BioCentury’s roundup of translational innovations also includes a study from Amgen and a newco spotlight

Plus: Series A for oncology play Noetik; China-based DualityBio files for Hong Kong IPO

Flagship company uses in silico screening to mine ‘Anthromolecules’ as starting points for pills targeting well-validated pathways, with an initial focus on I&I

Plus: AbbVie buys Celsius; Fosun offers to take Henlius subsidiary private; Coherus divests biosimilar of Humira

Plus: Bluejay, Vir give HDV updates; Skye’s miss in glaucoma; and more

Investors don’t like the move, slash $25B from its market cap

Plus: AZ cuts late-stage GLP-1, Wilson’s disease programs and updates from Sanofi, 4D Molecular, Generate

Humira has competition coming from IL-17 biologics, oral small